雾化芬太尼没有改善纤维化间歇性肺部疾病的运动能力或呼吸障碍
Charlotte Chen1, John Kolbe2, Julian F R Paton1
1Manaaki Manawa - The Centre for Heart Research, Department of Physiology, Faculty of Medical & Health Sciences, University of Auckland, Auckland, New Zealand.
Experimental physiology
|October 12, 2024
概括
雾化芬太尼在患有纤维化间歇性肺病 (FILD) 的患者中没有改善运动耐力或减少呼吸困难. 虽然它略微减少了每分钟通风,但该效应对于改善FILD患者的运动能力并没有临床意义.
科学领域:
- 肺部医学 肺部医学
- 呼吸系统生理学 呼吸系统生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 纤维化间歇性肺病 (FILD) 显著损害了运动能力,其特点是运动不耐受和运动性呼吸障碍.
- 肺关神经活动在调节通风和运动期间呼吸障碍的感觉方面发挥着至关重要的作用.
- 在FILD中异常的 afferent活动可能会导致运动限制,这表明潜在的治疗点.
研究的目的:
- 调查雾化芬太尼在减弱FILD患者肺 afferent活动中的疗效.
- 为了确定雾化芬太尼是否减少了运动期间的通风和呼吸障碍.
- 评估雾化芬太尼对FILD患者运动耐力时间 (EET) 的影响.
主要方法:
- 一个随机的,单盲,安慰剂控制的研究,涉及八名FILD患者.
- 患者在使用芬太尼酸盐 (100微克) 或盐水后进行了增量心肺循环运动测试.
- 测量包括休息和运动呼吸变量,博格呼吸障碍量级等级和运动耐力时间 (EET).
主要成果:
- 与安慰剂相比,雾化芬太尼没有显著增加EET (348s与334s,P=0.250).
- 与芬太尼 (-0.97 L/min,P=0.022),在运动期间观察到轻微减少分钟通风,但这在临床上没有显著意义.
- 在休息或运动期间的芬太尼和安慰剂条件之间没有报告呼吸障碍强度或不愉快的显著差异.
结论:
- 雾化芬太尼在改善FILD患者的运动耐力或减少炼性呼吸障碍方面没有显著的益处.
- 观察到的每分钟通风的减少是最小的,不太可能转化为运动能力的有意义的临床改善.
- 这些发现表明,将雾化芬太尼作为向肺静脉 afferents 可能不是有效的策略来管理FILD的运动限制.
相关概念视频
01:25Pulmonary Function Tests
311
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
311
01:23Inhaled Medications
237
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
237
01:26COPD: Management Using Bronchodilators and Corticosteroids
184
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
184
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
01:11Renal Failure: Dose Adjustments
68
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
68
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
180
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
180